Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
The Division of Rheumatology at University of California San Francisco is conducting a
research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently
used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a
protein that is given twice weekly by injection underneath the skin. It blocks the action of
tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid
arthritis, and other inflammatory conditions. We will randomly assign patients to receive
either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor
include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)